Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of SNP Variants in PON-1 or UGT1A1 on Iron Chelation Therapy Outcomes and Zinc Status in Thalassemia Major Patients.

Biological trace element research - 1 Apr 2026

Lu Meng-Yao, Tsai Wan-Fu, Wu Chang-Shiann, Wang Chien-Sheng, Syifa Nailis, Lu Mong-Liang, Liao Jiahn-Haur, Chen Wei J, Lin Kai-Hsin, Wu Tzu-Hua

Abstract excerpt

Factors affecting iron chelation therapy outcomes are complex and should be identified to tailor interventions to the needs of individuals with beta-thalassemia major (TM). The purpose of the study was to determine the effects of PON-1 or UGT1A1 single-nucleotide polymorphisms on therapeutic outcomes via deferasirox (DFX) and the antioxidant status. PON-1 (rs662) or UGT1A1 (rs887829) polymorphisms, iron chelation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Benzoates
Share to Aryldialkylphosphatase
Share to beta-Thalassemia
Share to Glucuronosyltransferase
Share to Iron
Share to Iron Chelating Agents
Share to Triazoles
Share to Zinc

Source

Identifiers

PMID: 40986213
DOI: 10.1007/s12011-025-04823-7

Genes

UGT1A1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of SNP Variants in PON-1 or UGT1A1 on Iron Chelation Therapy Outcomes and Zinc Status in Thalassemia Major Patients.PMID 40986213Read ↗

Iron Metabolism in Thalassemia and Sickle Cell Anemia: The influence of Genetic ModifiersSemantic proximity Read ↗

Pharmacogenetic Study of Deferasirox, an Iron Chelating AgentSemantic proximity Read ↗

Lifestyle and dietary factors, iron status and one-carbon metabolism polymorphisms in a sample of Italian women and men attending a Transfusion Medicine Unit: a cross-sectional study.Semantic proximity Read ↗

Pharmacogenomic and Clinical Predictors of Deferasirox Response in Transfusion-Dependent Thalassemia Identified Using Whole-Genome Sequencing.Semantic proximity Read ↗

TMPRSS6, but not TF, TFR2 or BMP2 variants are associated with increased risk of iron-deficiency anemia.Semantic proximity Read ↗

Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children.Semantic proximity Read ↗

Association of HBB Gene Variants with Laboratory Profiles and Comorbidities in Taiwanese beta thalassemia carriers: A Case–Control StudySemantic proximity Read ↗

Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors.Semantic proximity Read ↗

Association of Metallothionein 2A rs10636 with low mean cor-puscular volume (MCV), low mean corpuscular haemoglobin (MCH) in healthy TaiwaneseSemantic proximity Read ↗

Association of metallothionein 2A rs10636 with low mean corpuscular volume (MCV), low mean corpuscular haemoglobin (MCH) in healthy Taiwanese.Semantic proximity Read ↗

Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.Semantic proximity Read ↗

UGT1A6 variants and deferiprone-induced ADRs: a complication-specific analysis in Iranian thalassemia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.